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By contemporary conventions, the reporting of the results of 
clinical trials includes tabular summaries of end point inci- 
dence, illustrations of cumulative event curves in control 
and treatment groups and a description of the findings of 
statistical tests of the significance of differences between the 
two groups. Such displays of event data based on analytic 
methods introduced earlier this century by Berkson (l), 
Kaplan and Meier (2) and Mantel and Haenszel (3) offer 
explicit documentation of the quantitative differences be- 
tween the tested patient groups. This approach has been a 
hallmark in clinical trial reporting for three decades. 
such a 50% reduction in risk cannot be appreciated. Hence, 
if the percent risk reduction is reported out of context, it can 
be misleading to those who do not carefully contemplate the 
method of its calculation. 
Percent risk reduction. In recent therapeutic trials (4-U), 
a novel and seemingly popular measure of the difference 
between control and treatment groups has come to the fore. 
It is most commonly referred to as the percent risk reduction 
and has been variously termed percent reduction in mortal- 
ity, percent cardiac end point or event reduction and percent 
reduction in cumulative life table incidence. This measure is 
in essence the ratio of the difference in event frequency 
between control and treatment groups to the event fre- 
quency in the control group. It is calculated as (R, - R,) x 
100/R, or (l- R,/R,) x 100, where R, and R, are the event 
rates for the period of study in treatment and control groups. 
respectively. 
A secondproblem in interpreting percent risk reduction is 
the fact that, for any absolute reduction in events, the 
reported percent reduction in risk is directly dependent on 
the incidence of events in the control group. Figure 1 
illustrates the percent risk reduction that might be reported 
for a constant reduction from control of 5 events per 100 
when the frequency of events in the control group varies 
from 5 to 100%. At a 5% control level of event frequency, a 
reduction by 5 per 100 (that is, from 5% in control to 0% in 
treatment) would be reported as a 100% reduction in risk. At 
control levels of event frequency of 50% and lOO%, the same 
reduction in events would be reported, respectively, as 10% 
and 5% reductions in risk. Because of its method of calcu- 
lation, the percent risk reduction will exceed, and hence 
inflate, the percent difference between treatment and control 
levels at all levels of control event or mortality frequency 
Problems in interpreting percent risk reduction data. 
There are three basic problems relevant to the interpretation 
of percent risk reduction data. First, the percent risk reduc- 
tion reflects the relative frequency of events rather than their 
absolute difference. In paired groups of equal size, the same 
50% risk reduction could be reported for such widely varying 
event differences between treatment and control groups as 
0.1 versus 0.2, 1 versus 2, 10 versus 20,25 versus 50 or 100 
versus 200, and so forth. Without reference to the event 
incidence in the control group, the clinical significance of 
Figure 1. Dependence of the calculated percent reduction from 
control mortality on the control mortality level. *For a constant 
reduction in mortality (WIOO), the caiculated percent reduction from 
control mortality is inversely related to the control mortality rate. 
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Table 1. Recent Controlled Clinical Trials-Data Summary 
Study 
Timolol-AM1 (4) 
Propranolol-AMI (5) 
ASA-unstable angina (6) 
Cholestyramine-HC 171 
ASA-unstable angina (8) 
Streptokinase-AM1 (9) 
Vasodilators-CHF (10) 
Diltiazem-non Q AMI (I 1) 
Niacin-AM1 ( 12) 
Enalapril-CHF (13) 
Gemfibrozil-HC (14) 
ASA-normal subjects (15) 
Follow-Up+ 
33 mo 
25 mo 
12 weeks 
7 Yr 
2 Yr 
21 days 
1 yr 
2 yr 
3 yr 
14 days 
15 yr 
6 mo 
l yr 
5 yr 
57 mo 
Control 
17.5 
13.9 
9.8 
10. I 
7.8 
6.9 
8.6 
17.0 
11.7 
13.0 
19.5 
34.3 
46.9 
12.9 
58.2 
44.0 
52.0 
4.14 
1.71 
Event Rate (‘%“c) 
Reported 
Risk 
Reduction 
Rx Diff (%) (%) End Points 
10.6 6.9 39 All deaths 
7.1 6.2 45 Sudden death 
7.2 2.6 26 All deaths 
5.0 5.1 51 All deaths and non-fatal AMI 
3.5 4.3 55 Fatal and non-fatal AMI 
3.4 3.5 51 Non-fatal AMI 
7.0 1.6 19 Cardiac death and non-fatal AM1 
8.6 8.4 51 Cardiac death and non-fatal AMI 
3.0 8.7 71 All deaths 
10.7 2.3 I8 All deaths 
12.1 7.4 38 All deaths 
25.6 8.7 25 All deaths 
36.2 10.7 23 All deaths 
6.3 6.6 51 Reinfarction 
52.0 6.2 11 All deaths 
26.0 18.0 40 All deaths 
36.0 16.0 31 All deaths 
2.73 1.41 34 Cardiac death, fatal and non-fatal 
0.94 0.77 47 Fatal and non-fatal AM1 
*Refers to reported cumulative event rates for trials 4, 7. IO, 11, 12 and I4 and crude end point frequency for trials 5, 6. 8, 9. 13 and 15. Event rates were 
reported in percent for all trials except I4 and 15; percent event rates in trials I4 and 15 were calculated from the primary data. tFollow-up time at which event 
data and percent risk reduction are calculated. AMI = acute myocardial infarction: ASA = aspirin; CHF = congestive heart failure: Diff = difference between 
control and treatment in percent; HC = hypercholesterolemia; non Q = non Q wave; Rx = treatment. 
< 100%. Because the percent risk reduction is so dependent 
on the level of risk in the control group, it cannot be used to 
compare the potency of treatment modalities in different 
studies or in different populations, except in the rare circum- 
stance when the control event frequencies are identical. 
A third problem in the interpretation of percent risk 
reduction is stutistical. The level of probability of signili- 
cance for the difference in events between control and 
treatment groups is calculated from primary or cumulative 
event data. This probability level is not the same as that for 
the percent risk reduction. To interpret the significance of 
the reported percent risk reduction, one must be provided 
with knowledge of the range of its confidence limits. 
Summary of data from 12 recent trials. Table 1 summa- 
rizes the results of 12 recent clinical cardiovascular trials in 
which the percent reduction in risk (events, mortality or 
combined events) was reported (4-15). The percent mortal- 
ity or event frequency in control and treatment groups and 
their differences are shown. All data relate to the follow-up 
period for which percent risk reduction was calculated. Of 
note is the wide variation in the calculated percent risk 
reduction in relation to the difference in the percent of events 
between control and treatment groups. Thus, in the 7 year 
cholestyramine in hypercholesterolemia trial (7) a difference 
of 1.6 events per 100 between control and treatment groups 
is reported as a 19% reduction in events. In the 5 year 
gemfibrozil study (14), a difference of 1.41 events per 100 is 
reported as a 34% reduction in events. In the clinical trial of 
aspirin in normal male physicians (15) a difference of 0.77 
event per 100, during the 57 months of the trial, is reported 
as a 47% risk reduction. Clearly the percent risk reduction 
does not accurately express the difference in the percent of 
events between the control and treatment groups. 
Implications. There are clear limitations in the reporting 
of percent risk reduction: it does not reveal absolute differ- 
ences in events; when quoted out of context it may lead to an 
inflated view of the effect of relatively minor differences in 
events, and it does not provide a reliable index of difference 
in potency between agents. Why, then, is it so frequently 
used in recent publications? To attempt to answer this 
question let us turn once again to the data in Table 1. In each 
of the reported studies, the percent risk reduction apprecia- 
bly exceeded the difference in percent of events between 
control and treatment groups. In none of the reports were 
there data on the percent improvement in survival (or 
event-free survival), a figure that is likely to be less than the 
percent risk reduction in the range of control levels observed 
in these trials.* In five of the studies confidence limits for the 
*A higher numerical value for the percent reduction in risk (that is, events 
or mortality) than that for the percent improvement in survival will occur 
whenever the control event or mortality frequency is <50%. 
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percent risk reduction were not cited. It seems that the 
popularity of reporting the percent risk reduction lies in the 
simple appeal of a high percentage value. Thus, in advertise- 
ments in our professional journals and articles in the public 
media that are designed to promote immediate application of 
clinical trial results, the percent risk reduction is commonly 
reported without reference to the primary event incidence 
and without inclusion of confidence limits (1618). 
The results of a well controlled clinical trial are quite 
evident in the direct expressions that cumulative and pri- 
mary end point event data provide. The derivations from the 
basic data that are reported in the form of the percent 
reduction in risk, when quoted out of context, can lead to 
obfuscation of these results. If the reporting of percentage 
risk reduction is to be continued, we believe that the data 
must be accompanied by confidence limits and presented 
only in the context of the event data. This practice should be 
followed in all educational documents and in commercial 
advertisements in our journals. It is time to tighten our 
clinical trial reporting standards. 
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